Cancer Treatment Today » Myelodysplastic http://cancertreatmenttoday.org Knowledge is Power Thu, 26 Mar 2026 23:39:25 +0000 en-US hourly 1 How PNH and MDS are related and how to treat PNH present in MDS http://cancertreatmenttoday.org/how-pnh-and-mds-are-related-and-how-to-treat-pnh-preent-in-mds/ http://cancertreatmenttoday.org/how-pnh-and-mds-are-related-and-how-to-treat-pnh-preent-in-mds/#comments Wed, 14 Nov 2012 15:54:49 +0000 M Levin, MD http://cancertreatmenttoday.org/?p=9849 It is rare to have myelodysplastic syndrome(MDS) and paroxysmal noctunral hemoglobnuria(PNH) coexist as two full blown disorders but PNH cells can be present in MDS and PNH can resemble some features of MDS. Among acquired stem cell disorders, auch as myelodysplastic syndromes (MDS) and aplastic anaemia (AA), links between paroxysmal nocturnal haemoglobinuria (PNH) and AA, have been often described, whereas the relationship between MDS and PNH is not entirely clear. Many reports identified small PNH clone in both aplastic anemia or low-risk myelodysplastic syndrome and  hemolysis(breaking of red cells), which is a feature on PNH, is present to some degree (< 10%) in these conditions but that hemolysis does not contribute significantly to the underlying anemia. Using high-sensitivity flow cytometry, approximately 60% of patients with aplastic anemia and 20% of patients with low-risk MDS have been found to have a detectable population of PNH white and red cells. In these cases, the focus of treatment is on the Bone Marrow failure component of the disease, aplastic anemia or MDS. Hemolysis inside vessels is the dominant feature of classic PNH, and this process is blocked by the complement inhibitor eculizumab(Soliris). When hemolysis is the predominant feature, treatment should be directed to the PNH component. The large majority of patients with PNH/AA and PNH/MDS have relatively small PNH clones (< 10%) and require no specific PNH therapy; in these cases, treatment should focus on the underlying BM failure syndrome.

For Professional version see here

Iwanaga M, Furukawa K, Amenomori T, Mori

]]> http://cancertreatmenttoday.org/how-pnh-and-mds-are-related-and-how-to-treat-pnh-preent-in-mds/feed/ 0 Promacta for low platelets of acute leukemia or myelodysplasia http://cancertreatmenttoday.org/promacta-for-low-platelets-of-acute-leukemia-or-myelodysplasia/ http://cancertreatmenttoday.org/promacta-for-low-platelets-of-acute-leukemia-or-myelodysplasia/#comments Fri, 05 Oct 2012 02:36:19 +0000 M Levin, MD http://cancertreatmenttoday.org/?p=9406 Low platelet counts are a frequent symptom in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Eltrombopag(Promacta) might be a new option to treat this problem in these diseases, provided that it can be shown that it does not stimulate malignant growht. Unfortunately, there is no significant literature to support Promacta in the setting of ongoing treatment for AML with Vidaza or in MDS. Currenlty PROMACTA is not indicated for the treatment of thrombocytopenia due to causes of thrombocytopenia (eg, myelodysplasia or chemotherapy) other than chronic  ITP. Several studies showed that Eltrombopag was capable of increasing platelet production in patients with AML and MDS but the clinical significance of this observation remains unclear. Promacta is currenlty in a study: Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia, NCT01286038.

For Professional version see here

]]> http://cancertreatmenttoday.org/promacta-for-low-platelets-of-acute-leukemia-or-myelodysplasia/feed/ 0